By VETTAPHARMA reporter: Alnylam Pharmaceuticals, Inc. has reported strong financial performance for the fourth quarter and full year ending December 31, 2025, highlighted by net product revenues of $995 million in Q4 and $2,987 million for the full year, representing growth of 121 % and 81 %, respectively, compared with the same periods in 2024. This performance marked a significant commercial milestone for the RNA interference (RNAi) therapeutics pioneer.
Alnylam’s newly announced “Alnylam 2030” strategy signals notably more aggressive growth ambitions compared with broader pharmaceutical industry forecasts. While large-cap peers such as AstraZeneca have projected steady, incremental revenue expansion in the coming years, Alnylam is targeting transformative scale, backed by triple-digit percentage growth in its TTR franchise and a pipeline cadence that includes multiple clinical readouts, pivotal trials, and new IND filings within a single year. The company’s rapid shift to GAAP and non-GAAP profitability in 2025 further underscores the accelerated trajectory it aims to sustain as part of its long-term RNAi leadership strategy.
For the full year 2025, Alnylam achieved GAAP and non-GAAP profitability, a notable shift from prior losses, and projected continued sustainable growth in operating income going forward.
Alnylam’s results were driven largely by its total TTR franchise — including AMVUTTRA® (vutrisiran) and ONPATTRO® (patisiran) — which together posted $827 million and $32 million in global net product revenues, respectively, in Q4 2025, representing 151 % total TTR growth over the same quarter in 2024. For the full year, the combined TTR revenues reached $2,314 million for AMVUTTRA and $173 million for ONPATTRO, amounting to 103 % total TTR growth year-over-year.
In addition to financial results, Alnylam outlined its 2026 pipeline strategy and long-term ambitions under its newly launched “Alnylam 2030” plan. The strategy is designed to scale the company’s operations by focusing on durable leadership in transthyretin (TTR)-related diseases, sustained innovation, and exceptional financial performance. Among planned goals are four clinical readouts, three ongoing pivotal studies, three Phase 2 study initiations, and three or more new investigational new drug (IND) filings slated for the year.
Alnylam also reiterated its net product sales guidance for 2026, reinforcing its confidence in continued revenue expansion.
“The landmark approval of AMVUTTRA for ATTR-CM in the U.S. was a major accomplishment in 2025,” said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. She noted progress across the company’s RNAi portfolio, including the initiation of Phase 3 programs and the development of a next-generation enzymatic ligation-based RNAi manufacturing platform.
The company’s strong financial results and strategic goals illustrate Alnylam’s expanding role in the biotechnology sector, particularly within RNAi therapeutics, which aim to prevent, halt, or reverse diseases by targeting specific gene expressions.
Source credit:
- Alnylam Pharmaceuticals, Inc. (2026, February 12). Alnylam Pharmaceuticals reports fourth quarter and full year 2025 financial results and highlights recent period progress. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
